Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad Hudson

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Clinical Chemistry|March 30, 2016
Expected Dangerously Low Potassium ConcentrationsMichael Magguilli, Chad Hudson, Y Victoria Zhang
Pediatric Blood & Cancer|September 11, 2025
A Case of Blinatumomab Efficacy in RAM Immunophenotype/CBFA2T3::GLIS2 Fusion AMLMaya Ball-Burack, Andrew Menssen, Lisa Eidenschink Brodersen, et al.
Cytometry. Part B, Clinical Cytometry|April 4, 2023
The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual diseaseFan-Chi Hsu, Chad Hudson, Elisabeth R Wilson, et al.
Nature Medicine|May 12, 2026
CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trialJohn F DiPersio, Guenther Koehne, Nirali N Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2023
Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921Erica Brivio, Edoardo Pennesi, Marieke E Willemse, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Clinical Chemistry|March 30, 2016
Expected Dangerously Low Potassium ConcentrationsMichael Magguilli, Chad Hudson, Y Victoria Zhang
Pediatric Blood & Cancer|September 11, 2025
A Case of Blinatumomab Efficacy in RAM Immunophenotype/CBFA2T3::GLIS2 Fusion AMLMaya Ball-Burack, Andrew Menssen, Lisa Eidenschink Brodersen, et al.
Cytometry. Part B, Clinical Cytometry|April 4, 2023
The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual diseaseFan-Chi Hsu, Chad Hudson, Elisabeth R Wilson, et al.
Nature Medicine|May 12, 2026
CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trialJohn F DiPersio, Guenther Koehne, Nirali N Shah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2023
Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921Erica Brivio, Edoardo Pennesi, Marieke E Willemse, et al.
Pageof 1